化疗相关认知障碍与肾功能不全
本文综述了化疗相关认知障碍(CRCI)与肾功能不全(KD)的关联,探讨了KD对CRCI的潜在影响,并总结了二者在神经毒性、神经炎症、氧化应激、血管病变及电解质酸碱失衡等方面的共同发病机制。文章指出血脑屏障破坏可能是肾病患者抗癌药物脑渗透性增加的关键机制,提示KD可能加重抗癌药物的神经毒性并协同促进认知障碍,但尚需转化研究验证。
要点
- KD与癌症常共存,二者均与认知障碍相关,KD可能加重CRCI。
- 血脑屏障破坏可能是肾病患者抗癌药物脑渗透性增加的关键机制。
- CRCI与KD认知障碍共享神经毒性、神经炎症等发病机制。
核心结论
- 基于现有知识,癌症合并KD患者可能存在抗癌药物神经毒性增高及认知障碍协同加重的潜在风险,但需进一步转化研究验证。
研究设计与样本
- 本文为文献综述,探讨CRCI与KD的关联及KD对CRCI的潜在影响。
主要发现
- CRCI表现为注意力差、短期记忆障碍和普遍精神迟钝。
- KD认知障碍与CRCI共享神经毒性、神经炎症、氧化应激、血管病变及电解质酸碱失衡等发病机制。
- 血脑屏障破坏可能是肾病患者抗癌药物脑渗透性增加的关键机制。
局限性
- 本文为综述,所提出的KD加重CRCI的假设尚需进一步转化研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cancer and kidney diseases (KD) intersect in many ways resulting in worse outcomes. Both conditions are correlated with cognitive impairment, which can be exacerbated in cancer patients by known effects of many antineoplastic drugs on cognition, leading to a phenomenon known as chemotherapy-related cognitive impairment (CRCI). This manifests as poor attention span, disturbed short-term memory, and general mental sluggishness. This literature review explores CRCI and investigates the potential impact of KD on this phenomenon. Additionally, we highlight the shared pathogenetic mechanisms (including neurotoxicity, neuroinflammation, oxidative stress, vascular disease, electrolyte, and acid-base imbalances), clinical presentation and imaging findings between cognitive impairment in KD and CRCI. The disruption of the blood-brain barrier might be a key mechanism for increased brain permeability to anticancer drugs in nephropathic patients with cancer. Based on existing knowledge, we found a potential for heightened neurotoxicity of antineoplastic drugs and a synergistic potentiation of cognitive impairment in cancer patients with KD. However, further translational research is urgently required to validate this hypothesis.
引用
- Simeoni M, Mulholland MM, Workeneh BT, et al. Chemotherapy-related cognitive impairment and kidney dysfunction. Nephrol Dial Transplant. 2025. PMID: 40080088. doi:10.1093/ndt/gfae249
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。